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Abstract
Tissue glucocorticoid levels in the liver and adipose tissue are regulated by regeneration of inactive glucocorticoid by 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1) and inactivation by 5a- and 5b-reductases. A low carbohydrate diet
increases hepatic 11b-HSD1 and reduces glucocorticoid metabolism during weight loss in obese humans. We hypothesized
that similar variations in macronutrient proportions regulate glucocorticoid metabolism in obese rats. Male Lister Hooded
rats were fed an obesity-inducing ad libitum ‘Western’ diet (37% fat, n=36) for 22 weeks, then randomised to continue this
diet (n=12) or to switch to either a low carbohydrate (n=12) or a moderate carbohydrate (n=12) diet for the final 8 weeks.
A parallel lean control group were fed an ad libitum control diet (10% fat, n=12) throughout. The low and moderate
carbohydrate diets decreased hepatic 11b-HSD1 mRNA compared with the Western diet (both 0.760.0 vs 0.960.1 AU;
p,0.01), but did not alter 11b-HSD1 in adipose tissue. 5a-Reductase mRNA was increased on the low carbohydrate
compared with the moderate carbohydrate diet. Compared with lean controls, the Western diet decreased 11b-HSD1
activity (1.660.1 vs 2.860.1 nmol/mcg protein/hr; p,0.001) and increased 5a-reductase and 5b-reductase mRNAs (1.960.3
vs 1.060.2 and 1.660.1 vs 1.060.1 AU respectively; p,0.01) in the liver, and reduced 11b-HSD1 mRNA and activity (both
p,0.01) in adipose tissue. Although an obesity-inducing high fat diet in rats recapitulates the abnormal glucocorticoid
metabolism associated with human obesity in liver (but not in adipose tissue), a low carbohydrate diet does not increase
hepatic 11b-HSD1 in obese rats as occurs in humans.
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Introduction
Glucocorticoids are potent regulators of energy metabolism. In
addition to production by the adrenal glands, tissue glucocorticoid
levels are regulated by several enzymes, particularly 11b-
hydroxysteroid dehydrogenase type 1 (11b-HSD1). 11b-HSD1
functions in vivo to regenerate cortisol from inactive cortisone
(corticosterone from inactive 11-dehydrocorticosterone in rodents)
and is highly expressed in the liver and adipose tissue [1].
Glucocorticoids are metabolised primarily by 5a-reductase type 1
and 5b-reductase in the liver prior to further metabolism by 3a-
hydroxysteroid dehydrogenase, while 5a-reductase type 1 is also
present in adipose tissue [2]. Control of tissue glucocorticoids is
dysregulated in human obesity, with decreased cortisol levels in the
liver secondary to reduced 11b-HSD1 activity [3,4] and increased
5a- and 5b-reductase activity [5,6]. Conversely, 11b-HSD1
mRNA and activity are increased in adipose tissue [4,7–9],
amplifying tissue glucocorticoid levels. Similarly, in obese Zucker
rats, 5a- and 5b-reductase activities are increased and 11b-HSD1
is decreased in the liver, while 11b-HSD1 is increased in adipose
tissue [10,11]. The mechanism of these tissue-specific changes in
glucocorticoid metabolism is unknown, but may reflect abnormal
dietary intake in obesity.
Dietary macronutrient content is an important determinant of
metabolic health independent of changes in body weight [12,13],
and this may be partly mediated by changes in glucocorticoid
action. Glucocorticoids respond acutely to changes in nutritional
status, for example plasma cortisol concentrations rise within
minutes of eating [14], while tissue glucocorticoids are regulated
more chronically by dietary content. A diet-induced obesity model
using an ad libitum high fat diet (45% of total calories) for 3 weeks
in rats recapitulated the abnormal hepatic glucocorticoid metab-
olism observed in human obesity, with decreased 11b-HSD1 and
increased hepatic 5b-reductase activities, although this effect was
not maintained after 20 weeks [15]. However, in contrast to
human obesity, 11b-HSD1 activity was decreased in adipose tissue
on the high fat diet [15]. Similarly, mice fed a high fat diet (58%
fat) ad libitum for 2 or 18 weeks dramatically decreased 11b-
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epididymal adipose tissue but had no effect on hepatic 11b-
HSD1 [16].
In humans, several studies have examined the effect of
underfeeding on 11b-HSD1 but have found either increased
[17], unchanged [18], or decreased 11b-HSD1 [19] in subcuta-
neous adipose tissue after weight loss, while hepatic 11b-HSD1
activity was unaltered [17]. This inconsistency may be attributable
to the various dietary strategies used in these studies. We recently
examined the effects of dietary composition during weight loss in
obese humans, and found that a high fat-low carbohydrate (low
CHO) diet increased whole body (predominantly hepatic) 11b-
HSD1 activity and decreased 5a- and 5b-reductase activities
(measured using deuterated cortisol infusions) compared with a
moderate fat-moderate carbohydrate (moderate CHO) diet, with
no effect on subcutaneous adipose tissue 11b-HSD1 [20].
Furthermore, dietary regulation of 11b-HSD1 was independent
of changes in body weight.
The discordant results between human and rodent studies could
be due to differences in regulation of enzyme expression between
species, but the macronutrient content of the diets used in the
rodent studies differ markedly from those achievable in human
diets. In order to test whether dietary regulation of glucocorticoid
metabolism is similar between species, and potentially to establish
a model in which to dissect the mediators of the effects of diet, we
fed rats a human-equivalent ‘Western’ diet to induce obesity in
order to mimic the subjects who enrolled in our human study. We
then followed their responses to diets with similar macronutrient
content as the low CHO and moderate CHO diets previously used
in humans [20], and explored glucocorticoid metabolism in the
liver and adipose tissue.
Methods
Ethics Statement
All procedures were approved by the Animal Ethics Committee
of the Rowett Institute of Nutrition and Health (RINH), under the
UK Animals (Scientific Procedures) Act 1996.
Animals and Protocol
Details of the protocol have been described previously [21]. 48
male Lister Hooded rats were weaned at 19 days of age onto a
stock (control) diet (CRM (pellets), Special Diet Services, Essex,
UK). Caloric content of this diet was carbohydrate (CHO) 69%,
protein 22%, fat 9%. After 9 days on this diet (t=0 weeks), the rats
were randomised to two groups: a lean control group (n=12), fed
the control diet ad libitum for 30 weeks; and a diet-induced obesity
group (n=36), fed an ad libitum high fat ‘Western’ diet for 22
weeks (CHO 47%, protein 16%, fat 37%; prepared in-house at the
Rowett Institute of Nutrition and Health) [21]. After 22 weeks,
obese rats were randomised to 3 further sub-groups (n=12 each):
one group remained on the Western diet; a second was placed on a
ketogenic high fat-low carbohydrate (low CHO) diet (CHO 7%,
protein 37%, fat 56%); while a third was commenced on a
moderate fat-moderate carbohydrate (moderate CHO) diet (CHO
27%, protein 37%, fat 36%). The Western and moderate CHO
diets were iso-energetic while the low CHO was more energy
dense, due to the additional fat. The exact content of these diets
has been published in detail previously [21]. Casein was used for
the dietary protein. Maize oil was used for baseline fat content of
each in-house diet, with suet used to make up the additional fat on
the low CHO diet. Cornstarch was the main CHO source for each
diet with sucrose added to the ‘Western’ diet. All three sub-groups
were fed ad libitum for a further 8 weeks.
Rats were housed four to a cage for the first 18 weeks then singly
for the remaining 12 weeks, in a 12: 12 hour light: dark cycle
(0700–1900 h light). Energy intake was recorded daily by
measuring food intake per cage and the rats were weighed twice
weekly. In a sub-set of rats within each group 4-day collections of
faeces were used to estimate the apparent digestibility of the
various diets. Body composition was determined at 22 and 30
weeks using a MRI scanner (EchoMRI, Houston, Texas, USA).
Energy expenditure was estimated indirectly from incremental
digestible energy intake, minus an estimated urine energy loss, and
calculated changes in body energy deposition (based on fat and
lean composition). An oral glucose tolerance test (OGTT) was
performed after 28 weeks at 8am after overnight fasting, using
gavage of a 50% glucose solution equivalent to 2 g glucose/kg
body weight. Blood samples were taken by tail tip prior to gavage
then at 7, 15, 30, 60, 90 and 120 minutes. After 30 weeks, the rats
were anaesthetised and decapitated in the fed state at 1000 h.
Organs were immediately removed, including the liver and peri-
renal adipose tissue, snap-frozen on dry ice and stored at 280uC
until analysis.
Laboratory Measurements
Plasma insulin and glucose were analysed as described
previously [21]. Liver and peri-renal adipose tissue were analysed
for 11b-HSD1, 5a-reductase type 1, 5b-reductase (in liver only)
and glucocorticoid receptor a (GRa) mRNA transcript levels by
real time PCR. 30 mg of liver (or 100 mg adipose tissue) was
homogenised and RNA extracted using Qiagen RNeasy Mini kits
(West Sussex, UK), prior to quantification of RNA using the
Ribogreen quantitation kit (Molecular Probes, Eugene, OR). RNA
integrity was confirmed by agarose gel electrophoresis. cDNA was
synthesized from 500 ng RNA using the Promega Reverse
Transcription System (Madison, WI) and quantified using the
Lightcycler 480 detection system (Roche, West Sussex, UK). A
standard curve for each primer probe set was generated by serial
dilutions (in nuclease-free water) of complementary DNA pooled
from all rats. Samples were analysed in triplicate and the mean
values of RNA abundance interpolated from the standard curve to
calculate transcript levels. The mean of 18S and cyclophilin A was
used as internal control to normalise abundances of transcript
levels. The results are expressed as a proportion of the mean values
in controls. Reverse transcriptase negative controls and RNA
negative controls were used to confirm the absence of genomic
DNA. Primers and probes for 18S, GRa,5 a-reductase type 1 and
5b-reductase were purchased pre-made from Applied Biosystems
(Southampton, UK). Other primers/probes were custom ordered
from Applied Biosystems using the following sequences; cyclophi-
lin A (accession number NM_017101)–59 CCC ACC GTG TTC
TTC GAC AT 39 (forward), 59 GAA AGT TTT CTG CTG TCT
TTG GAA CT 39 (reverse), 59 6-FAM- CAA GGG CTC GCC
ATC AGC CGT- TAMRA 39 (probe); 11b-HSD1 (accession
number NM_017080)–59 TCA TAG ACA CAG AAA CAG CTT
TGA AA 39 (forward), 59 CTC CAG GGC GCA TTC CT 39
(reverse), 59 6-FAM- CTG GGA TAA TCT TGA GTC AAG
CTG CTC CC- TAMRA 39 (probe).
To assess 11b-HSD1 protein, 11b-HSD1 activity was measured
in adipose tissue and liver in the dehydrogenase direction, as
previously described [10], because dehydrogenase activity is more
stable than reductase in vitro. Briefly, 500 mg/ml total protein of
adipose tissue homogenate was incubated with 2 mM NADP,
0.2% glucose and 100 nM corticosterone (of which 10 nM 1,2,6,7-
[
3H]4-corticosterone (Amersham, Berkshire, UK)) at 37uC for
2 hours. Conversion to 1,2,6,7-[
3H]4-11-dehydrocorticosterone
was measured by HPLC with on line scintillation detection. For
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liver homogenate was incubated with the above concentrations of
NADP, glucose and corticosterone for 4 hours.
Hepatic 5b-reductase activity was measured in liver cytosol as
previously described [11]. Briefly, 100 mg/ml protein was
incubated in buffer (40 mM Na2HPO4, 1 mM dithiothreitol,
320 mM sucrose; pH 7.4), 2 mM NADPH and 2 mM corticoste-
rone (of which 10 nM 1,2,6,7-[
3H]4-corticosterone) at 37uC for
1 hour. Samples were analysed in duplicate and conversion to
1,2,6,7-[
3H]4-5b-tetrahydrocorticosterone was measured by
HPLC with on line scintillation detection. Hepatic 3a-hydroxy-
steroid dehydrogenase activity was measured in liver cytosol in an
identical procedure to the 5b-reductase assay described above,
using 2 mM5 a-dihydrotestosterone (of which 10 nM 1,2,4,5,6,7-
[
3H]6-5a-dihydrotestosterone) as the substrate while samples were
incubated in duplicate at 37uC for 2 hours. Conversion to [
3H]6-
3a-5a,17b-androstanediol was measured by HPLC with online
scintillation detection. 5a-Reductase activity was not measured
due to instability of protein in vitro [22].
Power Calculations and Statistical Analysis
Each dietary group comprised 12 rats, which provided a
minimum of 85% power to detect to p,0.05 a difference of 15%
between diets for the various mRNA transcripts at 30 weeks (8
weeks after any diet switch). Obese rats in the Western, low CHO
and moderate CHO groups were compared with each other, while
those in the Western group were also compared with lean rats on
the control diet. All statistical analyses were performed using SPSS
version 14. One way ANOVA with post-hoc testing using Fisher’s
least significant differences test was used to test for differences
between both 2 diets (control vs Western) and 3 diets (Western, low
CHO, moderate CHO). P,0.05 was considered significant. Data
are presented as mean 6 SEM.
Results
Body Composition and Biochemical Measurements
Body composition and biochemistry have been described in
detail previously [21]. Briefly, the Western diet successfully
induced an obese phenotype. After 22 weeks, rats fed the Western
diet were heavier than the control-fed rats (64965 vs 58069g ,
p,0.001), due to increased whole body fat mass (16964v s
8666g ,p ,0.001) with no significant difference in lean mass
(44463 vs 44865 g).
Amongst obese rats, the low CHO group gained similar weight
and fat mass to the Western group but lost lean mass, while those
on the moderate CHO diet lost both fat and lean mass (Table 1).
Lean rats on the control diet gained less weight than obese rats on
the Western diet. Mean energy intakes were highest in rats fed low
CHO, followed by those on Western, moderate CHO, and control
diets (Table 1). Estimated energy expenditure was increased on the
low CHO compared with the other three diets, and was increased
on the moderate CHO diet compared with control (both p,0.05).
In the OGTT at 28 weeks, fasting glucose was lower in the low
CHO versus the Western and moderate CHO groups (Table 1). In
addition, fasting insulin was lower on the low CHO and moderate
CHO diets compared with the Western diet, while the total insulin
area under the curve during the OGTT was lower on the
moderate CHO compared with the Western diet. Fasting insulin
and glucose were increased in the rats on the Western compared
with the control diet (Table 1), as was total glucose area under the
curve during the OGTT (p,0.001).
Effect of Obesity-Inducing Western Diet on
Glucocorticoid Metabolism
In the liver, 11b-HSD1 activity was significantly decreased on
the Western diet compared with control, although 11b-HSD1
mRNA levels were unaltered (Figure 1a/b). Hepatic 5a-reductase
type 1 and 5b-reductase mRNA were increased on the Western
diet (Figure 2), although 5b-reductase activity was not different.
Hepatic 3a-HSD activity was unaltered by the Western diet (data
not shown). GRa mRNA was also unchanged between the two
diets (Figure 3).
In peri-renal adipose tissue, both 11b-HSD1 mRNA and
activity were decreased on the Western versus control diet
(Figure 1c/d). GRa mRNA was also decreased on the Western
diet (Figure 3). In contrast with the liver, 5a-reductase type 1
Table 1. Body composition, energy intake and OGTT results after 30 weeks.
Control Western Low CHO Moderate CHO
Body weight (grams) 59069 67665 *** 651614 63369
###
Fat mass (g) 8366 19266 *** 189671 5 0 66
### {{{
Lean mass (g) 45665 44565 425684 4 1 67
Delta weight (22–30 wks) (g) 11642 5 63* * 1 5 65 22566
### {{{
Delta fat mass (22–30 wks) (g) 23621 9 62 *** 2163 22165
### {{{
Delta lean mass (22–30 wks) (g) 8631 62 2863
# 2963
#
Energy intakes (22–30 wks) (kcal/day) 68617 3 61 *** 8362
### 6961
# {{{
Fasting glucose (mmol/l) 6.460.2 7.260.2 ** 6.860.1
# 7.360.2
{
Fasting insulin (mU/l) 48610 7568* * 5 1 66
# 4863
##
OGTT Glucose AUC (mU/l per 2 h) 960617 1189629 *** 1120641 1163648
OGTT Insulin AUC (mU/l per 2 h) 1217362071 1644361976 1307061309 1135961124
#
Data presented as mean 6 SEM for lean controls (n=11), and diet-induced obese rats after 8 weeks on Western (n=12), low carbohydrate (low CHO) (n=12), and
moderate carbohydrate (moderate CHO) diets (n=12). Comparisons were made either between control and Western diets or between Western, low CHO and moderate
CHO diets by one way ANOVA with post-hoc testing using Fisher’s least significant differences test. ** p,0.01, *** p,0.001 Western vs control diet;
# p,0.05,
## p,
0.01,
### p,0.001 versus Western diet;
{ p,0.05,
{{{ p,0.001 vs low CHO diet. AUC=area under curve. OGTT=oral glucose tolerance test.
Footnote: The difference between body weight and the sum of lean and fat tissue was attributed to skeletal mass and gut contents, both of which gave a low MRI
signal.
doi:10.1371/journal.pone.0008779.t001
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(Figure 2).
Effect of Low and Moderate CHO Diets on Glucocorticoid
Metabolism in Obese Rats
Hepatic 11b-HSD1 mRNA was reduced on both low CHO and
moderate CHO diets compared with the Western diet with a
similar trend in activity (both p,0.1) (Figure 1a/b). There was no
difference in hepatic 11b-HSD1 mRNA or activity between the
low and moderate CHO diets. Hepatic 5a-reductase type 1
mRNA and 5b-reductase mRNA and activity were unchanged for
both the low CHO and moderate CHO diets compared with the
Western diet, however 5a-reductase type 1 mRNA was increased
on the low CHO versus the moderate CHO diet (Figure 2). 3a-
HSD activity in the liver was unaltered between the low CHO,
moderate CHO and Western diets (data not shown) as was GRa
mRNA (Figure 3).
In adipose tissue, 11b-HSD1 mRNA and activity (Figure 1c/d),
5a-reductase type 1 (Figure 2) and GRa (Figure 3) mRNA were
unaltered between the Western, low CHO and moderate CHO
diets.
Discussion
These data show that selective manipulations of dietary
macronutrient content alter peripheral glucocorticoid metabolism
in rats. The obesity-inducing ‘Western’ diet decreased liver 11b-
HSD1 activity and increased 5a- and 5b-reductase mRNA
compared with a low fat control diet, showing that a diet-induced
obesity rodent model recapitulates the abnormal hepatic gluco-
corticoid metabolism observed in obesity in humans and Zucker
rats [3,4,10,11]. The decrease in visceral adipose tissue 11b-HSD1
mRNA and activity on the Western diet, however, contrasts with
findings in obese humans [9,23,24], but is consistent with previous
work in rodents showing that high fat diets decrease 11b-HSD1 in
adipose tissue and liver [15,16]. In addition, we have shown that
GRa is regulated by dietary-induced obesity, as GRa mRNA
expression in adipose tissue was decreased on the Western diet
compared with lean controls, further reducing tissue glucocorti-
coid action.
Our dietary interventions closely paralleled those used in our
previous human study, in which obese patients were studied
during weight loss regimes using diets with varying CHO content
[20]. In contrast with the human study, however, the low CHO
diet did not increase hepatic 11b-HSD1 compared with the
Western or moderate CHO diets; in fact, both low CHO and
moderate CHO diets decreased hepatic 11b-HSD1 mRNA (with a
trend for enzyme activity) compared with the Western diet, while
there was no difference in direct comparison between the low
CHO and moderate CHO diets. Body weight was significantly
reduced in the rats on moderate CHO compared with low CHO
and Western diets, suggesting that dietary macronutrient content
regulates hepatic 11b-HSD1 independently of changes in body
weight in rats. The lower carbohydrate content of the low CHO
and moderate CHO diets may be the primary mediator of this
reduction in hepatic 11b-HSD1, however the significantly
increased protein content of both diets could also be responsible.
We have hypothesized that altered glucocorticoid metabolism in
the liver in obese humans is secondary to hyperinsulinaemia [20]
and can therefore be reversed by reducing carbohydrate intake.
However this is not consistent with the current rodent data. Both
low CHO and moderate CHO groups had lower fasting plasma
insulin than those on the Western diet (presented in detail in [21]),
but hepatic 11b-HSD1 decreased further rather than increased in
these groups. In addition, hepatic 5a-reductase type 1 mRNA was
increased on the low CHO compared with the moderate CHO
Figure 1. Hepatic and adipose tissue 11b-HSD1. Data presented as mean 6 SEM for lean controls (n=11, white columns), and diet-induced
obese rats after 8 weeks on Western (n=12, black columns), low carbohydrate (low CHO) (n=12, grey columns), and moderate carbohydrate (mod
CHO) diets (n=12, striped columns). a) Hepatic 11b-HSD1mRNA levels. b) Hepatic 11b-HSD1 activity. c) Peri-renal adipose 11b-HSD1 mRNA levels. d)
Peri-renal adipose 11b-HSD1 activity. The mean of 18S and cyclophilin A was used as internal control (IC) for mRNA data. mRNA transcript levels are
expressed as a proportion of the mean values in controls. * p,0.05, ** p,0.01, *** p,0.001 Western vs control. # p,0.05, ## p,0.01 versus
Western diet.
doi:10.1371/journal.pone.0008779.g001
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secondary to the rats losing weight on the moderate CHO diet
while those on the low CHO gained weight. Obesity is associated
with increased 5a-reductase activity in humans [5], while we
[20,25] and others [26] have previously shown that weight loss
reduces 5a-reductase activity. In contrast, 5b-reductase was
unaffected by dietary manipulation in obese rats.
In visceral adipose tissue, glucocorticoid metabolism and GRa
were unaltered between the Western, low CHO and moderate
CHO diets, which is consistent with humans [20]. While the
Western diet (with 37% fat) decreased 11b-HSD1 in adipose tissue
compared with control (9% fat), increasing the fat content further
from 37% to 56% (on low CHO) did not further alter adipose 11b-
HSD1, indicating there may be a threshold effect of dietary fat
content. In addition, rats on the moderate CHO had significant
weight loss without altering 11b-HSD1, indicating that dietary fat
regulation of adipose 11b-HSD1 is independent of both protein
and carbohydrate content, and also of changes in weight. Only
peri-renal adipose tissue was studied, so we do not know if dietary
regulation of 11b-HSD1 was similar in other adipose sites,
although dietary regulation of 11b-HSD1 has been observed
across all studied fat depots in mice [16].
Whilst the current data suggest important species differences
may exist that should be considered when extrapolating from
rodent to human glucocorticoid metabolism, some potential
confounders may help to explain the differences. For example,
Figure 2. Hepatic and adipose tissue 5a-reductase type 1 and 5b-reductase mRNA and activity. Data presented as mean 6 SEM for lean
controls (n=11, white columns), and diet-induced obese rats after 8 weeks on Western (n=12, black columns), low carbohydrate (low CHO) (n=12,
grey columns), and moderate carbohydrate (mod CHO) diets (n=12, striped columns). a) Hepatic 5a-reductase mRNA. b) Hepatic 5b-reductase
mRNA. c) Hepatic 5b-reductase activity. d) Peri-renal adipose tissue 5a-reductase mRNA. The mean of 18S and cyclophilin A was used as internal
control (IC). mRNA transcript levels are expressed as a proportion of the mean values in controls. ** p,0.01 Western vs control. { p,0.05 mod CHO vs
low CHO.
doi:10.1371/journal.pone.0008779.g002
Figure 3. Hepatic and adipose tissue GRa mRNA. Data presented as mean 6 SEM for lean controls (n=11, white columns), and diet-induced
obese rats after 8 weeks on Western (n=12, black columns), low carbohydrate (low CHO) (n=12, grey columns), and moderate carbohydrate (mod
CHO) diets (n=12, striped columns). a) Hepatic GRa mRNA. b) Peri-renal adipose tissue GRa mRNA. The mean of 18S and cyclophilin A was used as
internal control (IC). mRNA transcript levels are expressed as a proportion of the mean values in controls. * p,0.05 Western vs control.
doi:10.1371/journal.pone.0008779.g003
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diets were not energy isodense. The macronutrient content of
these diets was designed to closely mirror those used in the
human study, however the main component of dietary fat
(maize oil) had a lower saturated fat and higher mono-
unsaturated and poly-unsaturated content than the human
diets; it is possible that the type of dietary fat is important in
regulating glucocorticoid metabolism. Weight gain was also
different between diets, particularly on the moderate CHO diet
when the rats lost weight. The reasons for weight loss in the
moderate CHO group are unclear, but their energy intakes were
significantly lower than the other obese groups and in fact were
similar to those of the lean control group. Although 11b-HSD1
mRNA and activity closely correlated in adipose tissue, this was
not the case in liver with the Western diet. This lack of
correlation between transcript levels and activity has been
observed previously in the liver and other tissues [15,24,27]. We
also observed dissociated changes of 5b-reductase mRNA and
enzyme activity.
The mechanism through which dietary fat content decreases
hepatic and adipose tissue glucocorticoid regeneration is unknown.
Possible candidates are the peroxisome proliferator activated
receptors (PPARs), as dietary fats are the endogenous ligands for
PPARs. PPARa-agonists decrease 11b-HSD1 in the liver in mice
[28], while PPARc-agonists decrease 11b-HSD1 in rodent adipose
tissue [29,30]. Interestingly, these effects are not acutely observed
in humans [31], which could potentially account for the
differences in dietary regulation observed between species. The
liver X receptor (LXR) is another potential mediator of these
effects, as LXR decreases 11b-HSD1 in the liver and adipose
tissue [32,33]. Further work is required to fully understand these
mechanisms.
To conclude, we have shown that diet-induced obesity in rats
increases hepatic glucocorticoid metabolism by reducing 11b-
HSD1 and increasing 5a- and 5b-reductase expression, recapit-
ulating the abnormal metabolism observed in human obesity.
However, unlike in humans, a low carbohydrate diet does not
increase hepatic 11b-HSD1 in rats, indeed lower carbohydrate
content may decrease hepatic 11b-HSD1 further. Confirming
previous results in rodents, high dietary fat content reduces
glucocorticoid signalling by decreasing 11b-HSD1, and also GRa,
in adipose tissue. Conversely, hepatic 5a-reductase is increased in
association with increases in weight. Manipulation of dietary
composition may chronically regulate 11b-HSD1 resulting in
altered local glucocorticoid concentrations, which may modify the
metabolic efficacy of various dietary strategies.
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